Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00630851 | A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes | PHASE3 | COMPLETED | 249 | — | — | Oct 1, 2002 | Oct 1, 2004 | Mar 5, 2015 | 53 | Sweden, |
| NCT00006399 | Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease | PHASE2 | COMPLETED | 45 | — | — | Sep 1, 1999 | Mar 1, 2004 | Jan 15, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Donepezil (Aricept) | DRUG | Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment |
| Placebo | DRUG | Matching placebo tablets orally once daily for 6 months |
| Donepezil | DRUG | - |
| Estrogen | DRUG | - |
| Progesterone | DRUG | - |
Inclusion Criteria: * Probable or possible Alzheimer's disease * Living in skilled nursing home Exclusion Criteria: * Other types of dementia or psychiatric or neurologic disorders * Musculoskeletal disease